Anixa Biosciences (ANIX) said Tuesday it has entered into a letter of intent with Verdi Solutions to develop artificial intelligence-guided peptide vaccines, tailored to individual cancer patients.
Under the letter of intent, Anixa has a six-month exclusive right to finalize a transaction for the research, development, and commercialization of Verdi's cancer vaccines.
Anixa and Verdi are targeting to start clinical trials for personalized vaccines in the US, the biotechnology company said.
Verdi is also developing off-the-shelf cancer vaccines, combined with companion diagnostics, Anixa said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。